Tumor immunotherapy market size of nearly 30 billion, Yongtai biological landing on the Hong Kong Stock Exchange.

On July 10, Yongtai Bio (06978.HK), the first unit of cell immunotherapy, was listed on the main board of the Stock Exchange of Hong Kong, opening at HK$13.4 per share, up 21.82 per cent.
Yongtai Bio Chairman Tan Wei said that the company, as the first biotech unit in Hong Kong to focus on cell immunotherapy, raised funds to support scientific and technological research and development and product commercialization, mainly to support core products and research and development pipeline research and development work, research and development pipelines and products to Europe and the United States.
Yongtai bio-personalized immune cell products, is the only biopharmaceutical enterprise in 44 Beijing service industry expansion open comprehensive pilot units, its research and development of EAL ® (expanded activated lymphocytes) is currently the only domestic approved to enter the solid tumor treatment Phase II clinical trial of immune cell products, has been in Concord, 301 and other Beijing, Tianjin, Henan, Hebei, 14 sanacetogen hospitals in the field of clinical trial research, is expected to fill the field of physical tumor cell research.
2018, china has more than 400,000 new cases of liver cancer, accounting for 44.9% of new cases of liver cancer worldwide, and the five-year survival rate is only 12.1%, well below the five-year average of 40.5% of all cancers. Yongtai Bio Chairman Tan Wei told reporters that EAL ® plans to complete the first half of 2021 after the mid-term data analysis, will apply to the State Drug Administration conditional approval for listing.
Tan said that from an industry point of view, China's cancer immunotherapy track is huge, and there is still a lot of room for growth. The market size of tumor immunotherapy will be about RMB28.9 billion in 2018, 16.2% growth in 2013-2017 and 34.6% in 2018-2022.
.